Replies to post #167132 on Cytodyn Inc (CYDY)

[DonDonDonDon]

https://www.globenewswire.com/news-release/2021/05/18/2231343/19782/en/CytoDyn-to-Submit-Newly-Completed-Topline-Report-of-CD12-Trial-Results-to-Regulatory-Agencies-in-Multiple-Countries-including-India-and-Philippines.html

The results in the table above indicate that from day zero to day seven, critically ill patients receiving leronlimab (on day zero) experienced a mortality rate 78% lower than patients receiving placebo. Further, patients receiving the second dose of leronlimab achieved maximum benefit of 82% less mortality.

Read the above quote carefully. They say "mortality rate 78% lower" in the first sentence. But the second sentence says "achieved maximum benefit of 82% less mortality". The 82% number does not come from all 62 critical patients. I just tried every permutation of 19 placebo and 43 leronlimab and none came out to 82%. So my guess is that the 82% number comes from a subgroup within the 62 patients. Maybe it is only ECMO patients that received the "maximum benefit" of 82% less mortality. Or maybe it is an age group that received the "maximum benefit" of 82%. And the 82% is probably 63%.

The 82% mortality benefit at 14 days is 100% a lie! They had bad data so they datamined and manipulated the results to the maximum benefit!